These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16455347)

  • 41. Prophylactic effectiveness of suplatast tosilate in children with asthma symptoms in the autumn: a pilot study.
    Yoshihara S; Yamada Y; Fukuda H; Tsuchiya T; Ono M; Fukuda N; Kanno N; Arisaka O
    Allergol Int; 2014 Jun; 63(2):199-203. PubMed ID: 24561769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulators for allergic respiratory disorders.
    Casale TB; Stokes JR
    J Allergy Clin Immunol; 2008 Feb; 121(2):288-96; quiz 297-8. PubMed ID: 18269921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-inflammatory effect of suplatast tosilate on mild asthma.
    Sano Y; Miyamoto T; Makino S
    Chest; 1997 Sep; 112(3):862-3. PubMed ID: 9315837
    [No Abstract]   [Full Text] [Related]  

  • 44. Suplatast tosilate dimethylsulfonium treatment for steroid-dependent nephrotic syndrome.
    Ohtomo Y; Fujinaga S; Hattori M
    Pediatr Int; 2005 Apr; 47(2):230-1. PubMed ID: 15771702
    [No Abstract]   [Full Text] [Related]  

  • 45. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.
    Furonaka M; Hattori N; Tanimoto T; Senoo T; Ishikawa N; Fujitaka K; Haruta Y; Yokoyama A; Kohno N
    J Pharmacol Exp Ther; 2009 Jan; 328(1):55-61. PubMed ID: 18832650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs.
    Taniguchi H; Togawa M; Ohwada K; Kiniwa M; Matsuura N; Nagai H; Koda A
    Eur J Pharmacol; 1996 Dec; 318(2-3):447-54. PubMed ID: 9016937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids.
    Sano T; Nakamura Y; Yanagawa H; Bando H; Nii A; Yoshida S; Sone S;
    Lung; 2003; 181(4):227-35. PubMed ID: 14692563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells.
    Hsu LW; Yang CH; Goto S; Nakano T; Lai CY; Lin YC; Kao YH; Chen SH; Cheng YF; Jawan B; Chiu KW; Tsao FK; Chen CL
    Transpl Immunol; 2007 Nov; 18(2):108-14. PubMed ID: 18005853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid.
    Kirimoto T; Nakano K; Irimura K; Hayashi Y; Matsuura N; Kiniwa M; Oka T; Yoshimura N
    BJU Int; 2007 Oct; 100(4):935-9. PubMed ID: 17714534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IPD-1151T (suplatast tosilate) inhibits interleukin (IL)-13 release but not IL-4 release from basophils.
    Shichijo M; Shimizu Y; Hiramatsu K; Togawa M; Inagaki N; Takagi K; Nagai H
    Jpn J Pharmacol; 1999 Apr; 79(4):501-4. PubMed ID: 10361893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A case report of eosinophilic cystitis treated with oral suplatast tosilate].
    Kuramoto T; Senzaki H; Inagaki T
    Hinyokika Kiyo; 2014 Sep; 60(9):447-50. PubMed ID: 25293800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A case of recurrent cutaneous eosinophilic vasculitis: successful adjuvant therapy with suplatast tosilate.
    Sakuma-Oyama Y; Nishibu A; Oyama N; Saito M; Nakamura K; Kaneko F
    Br J Dermatol; 2003 Oct; 149(4):901-3. PubMed ID: 14616398
    [No Abstract]   [Full Text] [Related]  

  • 54. Azelastine and suplatast shorten the distribution half-life of IgE in rats.
    Hanashiro K; Tokeshi Y; Nakasone T; Sunagawa M; Nakamura M; Kosugi T
    Mediators Inflamm; 2002 Feb; 11(1):61-4. PubMed ID: 11926596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
    Cruz AA; Lima F; Sarinho E; Ayre G; Martin C; Fox H; Cooper PJ
    Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Th2 cytokine inhibition and cough in asthmatic and bronchitic patients.
    Ishiura Y; Fujimura M; Nobata K; Myou S; Oribe Y; Abo M; Nakamura H
    Ann Med; 2004; 36(8):623-9. PubMed ID: 15768834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel treatments of asthma and allergic diseases.
    Chini L; Monteferrario E; Graziani S; Moschese V
    Paediatr Respir Rev; 2014 Dec; 15(4):355-62. PubMed ID: 24287269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The appropriate omalizumab patient.
    Karpel J; Bukstein DA; LoNigro R
    Manag Care; 2007 May; 16(5):44-50, 56. PubMed ID: 17552338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.